Get the Stockscreener App
19.91
7.62%
1.41
Pre-market:
19.99
0.08
+0.40%
Summit Therapeutics Inc stock is traded at $19.91, with a volume of 2.76M.
It is up +7.62% in the last 24 hours and up +1.74% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$18.50
Open:
$19.36
24h Volume:
2.76M
Relative Volume:
1.18
Market Cap:
$14.69B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-82.96
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
+1.84%
1M Performance:
+1.74%
6M Performance:
-27.36%
1Y Performance:
+361.95%
1-Day Range:
$19.27
$20.50
1-Week Range:
$16.55
$20.50
52-Week Range:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.91 | 14.69B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN
Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com
Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks
Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq
Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada
Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey
New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World
(SMMT) Investment Analysis and Advice - Stock Traders Daily
Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat
Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN
StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks
Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target -February 28, 2025 at 08:12 am EST - Marketscreener.com
Summit Therapeutics's Options Frenzy: What You Need to Know - Benzinga India
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 15.6%Time to Sell? - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Brokerages Set Summit Therapeutics Inc. (NASDAQ:SMMT) Price Target at $33.57 - MarketBeat
Summit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to Analysts - MSN
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown - MSN
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Earnings Call Transcript - MSN
Why Summit Therapeutics Inc. (SMMT) Went Down On Monday? - Insider Monkey
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - MSN
Positive Outlook for Summit Therapeutics: Strategic Collaborations and Promising Trials Justify Buy Rating - TipRanks
Summit inks ADCs deal with Pfizer - The Pharma Letter
Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Buy Rating for Summit Therapeutics Driven by Strategic Pfizer Collaboration and Promising Clinical Trial Readouts - TipRanks
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus.com
Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Summit Therapeutics: Strong Financials and Strategic Collaborations Drive Buy Rating - TipRanks
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs - Lelezard
15 Stocks That Will Go to The Moon According to Analysts - Insider Monkey
Summit Therapeutics Reports 2024 Financials and Progress - TipRanks
Summit Therapeutics Highlights Q4 Results and FDA Fast Track - TipRanks
Can This Summit-Pfizer Cancer Drug Combo Revolutionize Solid Tumor Treatment? - StockTitan
SMMTSummit Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Earnings call transcript: Summit Therapeutics Q4 2024 sees stock drop 13.6% - Investing.com Australia
U.S. Markets Closed Mixed Monday As Sun Communities Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program (SMMT) - Seeking Alpha
Stifel maintains Summit Therapeutics at Hold with $40 target - Investing.com
Stifel maintains Summit Therapeutics at Hold with $40 target By Investing.com - Investing.com South Africa
Summit Therapeutics falls on wider Q4 loss, deal expectations from investors - TradingView
Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT) - StreetInsider.com
Summit Therapeutics announces clinical trial collaboration with Pfizer - MSN
Summit Therapeutics advances ivonescimab with Pfizer collaboration and expanded trials - MSN
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):